Actively Recruiting
Phase 2 Study of AMDX-2011P Intravenous Injection as a Retinal Tracer for Adults With Cerebral Amyloid Angiopathy
Led by Amydis Inc. · Updated on 2026-02-13
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, plasma pharmacokinetics, and biological activity of a single intravenous dose of AMDX-2011P in adults with cerebral amyloid angiopathy CAA. This open-label, phase 2 study aims to understand how this drug behaves in the body and its effects related to CAA, a condition characterized by the accumulation of amyloid in the brains blood vessels. The study also involves retinal imaging assessments conducted by masked reviewers to explore the drugs diagnostic potential. Participants will receive a single intravenous bolus injection of 100 mg AMDX-2011P. Before the injection, participants undergo eye examinations and retinal imaging. After administration, safety assessments, additional retinal imaging, and blood samples for pharmacokinetic analysis will be collected. The study primarily monitors adverse events over 8 days, with pharmacokinetic and biological activity evaluations within the first 2 hours following the dose. During the study, participants will be admitted to the study site for all procedures including eye exams, imaging, drug administration, and safety monitoring. Researchers will track the drugs concentration in plasma, assess any side effects, and evaluate biological activity. The total monitoring period for adverse events extends for 8 days after dosing. This study is sponsored by Amydis Inc. and is expected to conclude in December 2026.
CONDITIONS
Brief Title
A Study of AMDX-2011P in Participants With CAA
Research Team
M
Matthew Lehman
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here